The MarketWatch News Department was not involved in the creation of this content. 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 ug/kg ...

- The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. - Most patients, 81.6% (594/728), entered ...

Zoryve cream helped 63.1% of children aged 2–5 reach vIGA-AD 0/1 after 56 weeks. Only 2.5% of kids aged 2–5 experienced treatment-related side effects in the study. Get special access to three ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an IL-2 receptor agonist. Patients saw improvements in EASI, vIGA-AD and Itch NRS scores.

DENVER – Topical roflumilast (Zoryve) cream 0.05% showed favorable efficacy and safety in children 3 months to up to 2 years of age with mild-to-moderate atopic dermatitis, according to new data ...

Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for ...

71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses ...